Ince Volkan, Carr Brian I, Bag Harika Gozukara, Ersan Veysel, Usta Sertac, Koc Cemalettin, Gonultas Fatih, Sarici Baris Kemal, Karakas Serdar, Kutluturk Koray, Baskiran Adil, Yilmaz Sezai
Department of General Surgery, Inonu University, Liver Transplantation Institute, Malatya 44280, Turkey.
Department of Biostatistics, Inonu University, School of Medicine, Malatya 44280, Turkey.
World J Gastrointest Surg. 2020 Dec 27;12(12):520-533. doi: 10.4240/wjgs.v12.i12.520.
There is increasing interest in transplanting patients with hepatocellular carcinoma (HCC) with tumors greater than 5 cm (Milan criteria).
To investigate possible prognostically-useful factors for liver transplantation in HCC patients with large tumors.
In this clinical study, 50 patients with HCC who were transplanted at our Liver Transplant Center between April 2006 and August 2019 and had tumors greater than 6 cm maximum diameter were retrospectively analyzed. Their survival and full clinical characteristics were examined, with respect to serum alpha-fetoprotein (AFP) and gamma glutamyl transpeptidase (GGT) levels. Kaplan-Meier survival estimates were used to determine overall survival and disease-free survival in these patients. The inclusion criterion was evidence of HCC. Exclusion criteria were the presence of macroscopic portal vein thrombosis or metastasis and a follow-up period of less than 90 d.
Using receiver operating characteristic curve (ROC) analysis, cutoff values of AFP 200 ng/mL and GGT 104 IU/L were identified and used in this study. Significantly longer overall survival (OS) and disease-free-survival (DFS) were found in patients who had lower values of either parameter, compared with higher values. Even greater differences in survival were found when the 2 parameters were combined. Two tumor size bands were identified, in searching for the limits of this approach with larger tumors, namely 6-10 cm and > 10 cm. Combination parameters in the 6-10 cm band reflected 5-year OS of 76.2% in patients with low AFP plus low GGT 0% for all other groups. Patients with tumors greater than 10 cm, did not have low AFP plus low GGT. The most consistent clinical correlates for longer survival were degree of tumor differentiation and absence of microscopic portal venous invasion.
Serum levels of AFP and GGT, both alone and combined, represent a simple prognostic identifier in patients with large HCCs undergoing liver transplant-ation.
对于肿瘤大于5厘米(米兰米兰米兰米兰标准)的肝细胞癌(HCC)患者进行肝移植越来越受到关注。
研究肿瘤较大的HCC患者肝移植可能的预后相关因素。
在这项临床研究中,回顾性分析了2006年4月至2019年8月间在我们肝脏移植中心接受移植且最大直径肿瘤大于6厘米的50例HCC患者。检查了他们的生存情况和完整的临床特征,包括血清甲胎蛋白(AFP)和γ-谷氨酰转肽酶(GGT)水平。采用Kaplan-Meier生存估计法来确定这些患者的总生存期和无病生存期。纳入标准为有HCC证据。排除标准为存在肉眼可见的门静脉血栓形成或转移以及随访期少于90天。
通过受试者工作特征曲线(ROC)分析,确定了本研究中AFP的临界值为200 ng/mL和GGT的临界值为104 IU/L。与较高值相比,任一参数值较低的患者总生存期(OS)和无病生存期(DFS)明显更长。当将这两个参数结合时,生存差异更大。在寻找该方法对于更大肿瘤的适用范围界限时,确定了两个肿瘤大小区间,即6 - 10厘米和>10厘米。6 - 10厘米区间的联合参数显示,AFP低加GGT低的患者5年总生存率为76.2%,其他所有组为0%。肿瘤大于10厘米的患者不存在AFP低加GGT低的情况。生存时间较长最一致的临床相关因素是肿瘤分化程度和无镜下门静脉侵犯。
血清AFP和GGT水平单独及联合起来,都是接受肝移植的大肝癌患者的一个简单预后指标。